May 6, 2020
Transgene posts €35.3 million in cash and cash equivalents in Q1 2020
Transgene posts €35.3 million in cash and cash equivalents in Q1 2020, with minor impact from the Covid-19 pandemic seen to-date
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
May 5, 2020
Sanofi, Regeneron plan submitting for Libtayo
Sanofi and Regeneron plan to submit this year their product Libtayo, which has shown in a pivotal trial with certain patients with advanced basal cell carcinoma, that it has meaningful and durable responses.
May 5, 2020
Centogene to globalize COVID-19 testing
Centogene said Tuesday it will expand its testing efforts for the novel coronavirus, or COVID-19, from previously testing in Germany’s Mecklenburg-Western Pomerania region, to now offering its extensively validated SARS-CoV-2 RT-PCR testing to the rest of the world.
May 5, 2020
Bayer, NeoGenomics launch Test4TRK program to provide free genomic cancer Testing
Bayer to cover testing costs for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma (DTC) and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H).
May 5, 2020
Vifor Pharma’s partner Akebia with positive cardiovascular outcomes program testing vadadustat,
Akebia’s vadadustat, an investigational oral HIF-PHI, achieves primary efficacy and cardiovascular safety endpoints.
May 5, 2020
ICON appoints new Chief Medical Officer
ICON has appointed Dr. Kristen K. Buck as the new Chief Medical Officer (CMO), who joined from Optum Insights .
May 4, 2020
Why Pharma product launch strategy really matters for businesses?
During the COVID-19 crisis, it is critical for companies in the pharmaceutical market to take calculative and well-executed measures to ensure business continuity in the long run.
May 1, 2020
Shionogi expecting Fetcroja available in coming weeks
Shionogis’ Fetcroja (cefiderocol) in the end of April 2020 received European Commission (EC) marketing authorisation for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options.
May 1, 2020
Vertex bags CHMP Positive Opinion for Kalydeco in EU
If approved, Kalydeco (ivacaftor) will be the first and only medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, as young as 6 months of age.
April 29, 2020
Genespire bags €16M for transformative gene therapies
Genespire has secured an injection of $16M in A financing round, and also has named a new CEO, with new board members joining in.